# Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

> **NCT05576623** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cellid Co., Ltd.** · enrollment: 320 (actual)

## Conditions studied

- COVID-19
- Vaccines

## Interventions

- **BIOLOGICAL:** AdCLD-CoV19-1 OMI (Part A)
- **BIOLOGICAL:** AdCLD-CoV19-1 OMI (Part B)
- **OTHER:** Placebo (Part B)

## Key facts

- **NCT ID:** NCT05576623
- **Lead sponsor:** Cellid Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2023-03-10
- **Final completion:** 2024-02-28
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576623, "Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05576623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*